Compare JJSF & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | DRTS |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | Israel |
| Employees | 1800 | N/A |
| Industry | Specialty Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 1995 | 2021 |
| Metric | JJSF | DRTS |
|---|---|---|
| Price | $94.53 | $11.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $121.50 | $20.60 |
| AVG Volume (30 Days) | 189.3K | ★ 586.0K |
| Earning Date | 11-18-2026 | 11-19-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $1,022,038,000.00 | N/A |
| Revenue This Year | $2.63 | N/A |
| Revenue Next Year | $2.22 | $1,805.76 |
| P/E Ratio | $47.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $68.87 | $3.65 |
| 52 Week High | $99.72 | $15.79 |
| Indicator | JJSF | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 64.80 | 37.14 |
| Support Level | $71.91 | $11.49 |
| Resistance Level | N/A | $14.60 |
| Average True Range (ATR) | 3.32 | 0.85 |
| MACD | 0.57 | -0.20 |
| Stochastic Oscillator | 67.21 | 20.68 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.